Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

Future GB logo

 

FUTURE-GB, an NIHR EME funded study, has opened with Southmead Hospital in Bristol as the first recruiting site.  Glioblastoma (GB) is the most common primary brain tumour and is incurable -with a poor prognosis for most patients. FUTURE-GB is a 2-stage trial, looking at the use of additional imaging technologies before and during adult glioblastoma surgery to improve patient outcomes and quality of life. Stage 1 of the trial is an IDEAL IIB study, with each patient receiving the additional imaging to ensure standardisation of practice with the technologies at each recruiting site. Stage 2 is the full randomised controlled trial, recruiting 357 participants from 15 neurosurgical centres across the UK. The whole trial will recruit for 33 months, and patient quality of life will be assessed for up to 2 years.

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.